Viral respiratory infections in children with technology dependence and neuromuscular disorders

Pediatric Infectious Disease Journal

Volumn 23, Issue 11 SUPPL., 2004, Pages

  Panitch, Howard B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bronchopulmonary dysplasia; Influenza virus; Long term oxygen therapy; Mechanical ventilation; Respiratory syncytial virus

Indexed keywords

CHILD; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; HEALTH SURVEY; HOSPITALIZATION; HUMAN; LUNG CLEARANCE; LUNG DYSPLASIA; NEUROMUSCULAR DISEASE; OXYGEN SUPPLY; PRIORITY JOURNAL; RISK FACTOR; VIRAL RESPIRATORY TRACT INFECTION; ARTICLE; CHRONIC DISEASE; FEMALE; HANDICAPPED CHILD; INFANT; MALE; MORBIDITY; MUSCLE WEAKNESS; NEWBORN; OXYGEN THERAPY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; VIROLOGY; VIRUS INFECTION;

CHILD, PRESCHOOL; CHRONIC DISEASE; DISABLED CHILDREN; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MORBIDITY; MUSCLE WEAKNESS; NEUROMUSCULAR DISEASES; OXYGEN INHALATION THERAPY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 16544395401     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000144670.78558.c7     Document Type: Conference Paper

References (32)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.
2. Souza LS, Ramos EA, Carvalho FM, et al. Viral respiratory infections in young children attending day care in urban Northeast Brazil. Pediatr Pulmonol. 2003;35:184-191.
3. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143: S127-S132.
4. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J. 2002;21:629-632.
5. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-9.
6. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283:499-505.
7. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992;121:348-354.
8. American Academy of Pediatrics-Committee on Infectious Disease. RED BOOK 2003: Policy Statement: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-1446.
9. Parnes C, Guillermin J, Habersang R, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35:484-489.
10. Panitch HB, Cohen A, Boron M, Van Veldhuisen P, Ciesla G. Physician survey on viral pathogens and respiratory disease in technology-dependent children [abstract]. Pediatr Res. 2004;55:603A.
11. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865-870.
12. Passerotti LA, Walters W, Desai V, Otegbeye A. A cost savings projection for respiratory syncytial virus immunization of older children with a history of bronchopulmonary dysplasia [abstract]. Pediatrics. 1999;104(suppl):677.
13. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003;88:1065-1069.
14. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988;82:199-203.
15. Arnold SR, Wang EE, Law BJ, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J. 1999;18: 866-869.
16. Talmaciu I, Ren CL, Kolb SM, Hickey E, Panitch HB. Pulmonary function in technology-dependent children 2 years and older with bronchopulmonary dysplasia. Pediatr Pulmonol. 2002;33:181-188.
17. Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med. 1988;319:1112-1117.
18. Martinez FD, Morgan WJ, Wright AL, Holberg C, Taussig LM. Initial airway function is a risk factor for recurrent wheezing respiratory illnesses during the first three years of life: Group Health Medical Associates. Am Rev Respir Dis. 1991;143:312-316.
19. Young S, Arnott J, O'Keeffe PT, Le Souef PN, Landau LI. The association between early life lung function and wheezing during the first 2 yrs of life. Eur Respir J. 2000;15:151-157.
20. Panitch HB, Clayton RG, Allen JL. Can lung mechanics identify infants with bronchopulmonary dysplasia (BPD) at risk for hospitalization from respiratory syncytial virus (RSV) infection? [abstract]. Am J Respir Crit Care Med. 1999;159:A154.
21. Tepper RS, Reister T. Forced expiratory flows and lung volumes in normal infants. Pediatr Pulmonol. 1993;15:357-361.
22. Clement A, Masliah J, Housset B, et al. Decreased phosphatidyl choline content in bronchoalveolar lavage fluids of children with bronchopulmonary dysplasia: a preliminary investigation. Pediatr Pulmonol. 1987; 3:67-70.
23. Coalson JJ, King RJ, Yang F, et al. SP-A deficiency in primate model of bronchopulmonary dysplasia with infection: in situ mRNA and immunostains. Am J Respir Crit Care Med. 1995;151:854-866.
24. Bancalari E, del Moral T. Bronchopulmonary dysplasia and surfactant. Biol Neonate. 2001;80(suppl 1):7-13.
25. Pandit PB, Dunn MS, Kelly EN, Perlman M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics. 1995;95:851-854.
26. Awasthi S, Coalson JJ, Crouch E, Yang F, King RJ. Surfactant proteins A and D in premature baboons with chronic lung injury (bronchopulmonary dysplasia): evidence for an inhibition of secretion. Am J Respir Crit Care Med. 1999;160:942-949.
27. Griese M. Respiratory syncytial virus and pulmonary surfactant. Viral Immunol. 2002;15:357-363.
28. Lahti M, Lofgren J, Marttila R, et al. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res. 2002;51:696-699.
29. Lofgren J, Ramet M, Renko M, Marttila R, Hallman M. Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. J Infect Dis. 2002;185:283-289.
30. Mier-Jedrzejowicz A, Brophy C, Green M. Respiratory muscle weakness during upper respiratory tract infections. Am Rev Respir Dis. 1988;138:5-7.
31. American Academy of Pediatrics-Committee on Infectious Disease. RED BOOK 2003: Technical report: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1447-1452.
32. Speer M, Cohen A, Boron M, Rankin M, Synagis Outcomes Registry Group. Results from the 2002-03 palivizumab Outcomes Registry: focus on congenital airway abnormalities and neuromuscular disease [abstract]. Pediatr Res. 2004;55:237A-238A.